When DOACs Are NOT Used in Atrial Fibrillation
DOACs are actually the preferred first-line anticoagulation for most patients with atrial fibrillation, but they have specific absolute contraindications where they must be avoided: mechanical heart valves, moderate-to-severe mitral stenosis, and end-stage kidney disease (CrCl <15 mL/min or dialysis). 1, 2
Absolute Contraindications to DOACs
DOACs are contraindicated in the following situations where warfarin must be used instead:
Mechanical heart valves - DOACs have not demonstrated safety or efficacy in this population and are absolutely contraindicated 1, 2
Moderate-to-severe mitral stenosis - Patients with rheumatic mitral stenosis were excluded from all major DOAC trials and should receive warfarin 1, 3
End-stage chronic kidney disease - Patients with CrCl <15 mL/min or on dialysis cannot safely use DOACs due to unpredictable drug accumulation and bleeding risk 1, 2
Severe liver disease (Child-Pugh C) - DOACs undergo hepatic metabolism and are contraindicated in advanced cirrhosis 1
Rivaroxaban specifically is contraindicated in Child-Pugh B (moderate) liver disease due to increased bleeding risk 1
Situations Requiring Caution (Not Absolute Contraindications)
The following scenarios require dose adjustment or careful consideration but are not contraindications:
Moderate chronic kidney disease (CrCl 15-50 mL/min) - DOACs can be used with appropriate dose reduction per drug-specific criteria 1, 2
Mild-to-moderate liver disease (Child-Pugh A or B) - DOACs are reasonable and preferred over warfarin, except rivaroxaban in Child-Pugh B 1
Bioprosthetic heart valves - DOACs can be safely used after the initial post-operative period 3, 4
Mild mitral stenosis - Limited evidence exists, but DOACs may be considered though more data are needed 5, 3
Why DOACs Are Actually Preferred When NOT Contraindicated
The 2024 ESC and 2023 ACC/AHA guidelines strongly recommend DOACs over warfarin for stroke prevention in eligible AF patients because they provide:
50% reduction in intracranial hemorrhage compared to warfarin 1
19% reduction in stroke or systemic embolism (HR 0.81,95% CI 0.73-0.91) 1
10% reduction in all-cause mortality (HR 0.90,95% CI 0.85-0.95) 1
No significant difference in major bleeding overall (HR 0.86,95% CI 0.73-1.00) 1
Common Pitfalls Leading to Inappropriate DOAC Avoidance
Clinicians often inappropriately withhold DOACs in situations where they should be used:
Advanced age alone is not a contraindication - elderly patients benefit from DOACs with appropriate dose adjustment 1, 6, 7
Fall risk is not a contraindication - the benefit of stroke prevention outweighs bleeding risk in most cases 6
Mild-to-moderate renal impairment requires dose adjustment, not avoidance 1, 2
Polypharmacy in stable elderly patients may favor continuing warfarin if already well-controlled (TTR >70%), but is not a reason to avoid DOACs in new patients 1
Critical Dosing Errors to Avoid
Underdosing DOACs without meeting specific criteria is harmful and increases stroke risk without reducing bleeding:
15-28% of patients receive inappropriately low DOAC doses in real-world practice 8, 9
Reduced doses should only be used when meeting drug-specific criteria - arbitrary dose reduction increases thromboembolic events 1, 8
For apixaban: reduce to 2.5 mg twice daily only if patient meets 2 of 3 criteria: age ≥80 years, weight ≤60 kg, or creatinine ≥133 μmol/L 1, 2
For dabigatran: reduce to 110 mg twice daily if age ≥80 years or receiving verapamil 1, 2